Denileukin diftitox and hyper-CVAD in the treatment of human T-cell lymphotropic virus 1-associated adult T-cell leukemia/lymphoma

Gina DiVenuti, Ranjana Nawgiri, Francine Foss

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

We report a case of human T-cell lymphotropic virus 1 (HTLV-1)-associated adult T cell leukemia/lymphoma (ATL) in clinical remission > 1 year after therapy with denileukin diftitox and hyper-CVAD (hyperfractionated cyclophosphamide/doxorubicin/vincristine/decadron). The patient presented with leukocytosis, anemia, and thrombocytopenia, and bone marrow biopsy demonstrated extensive myelofibrosis and infiltration with leukemic T cells. Initial therapy with 4 cycles of denileukin diftitox resulted in restoration of normal hematopoiesis and a reduction in bone marrow myelofibrosis. After disease progression, 4 cycles of hyper-CVAD were administered and a complete clinical remission was achieved. The patient remains free of disease with normal hematopoiesis and has continued maintenance therapy with denileukin diftitox for 1 year. This case demonstrates clinical improvement of myelofibrosis and acute T-cell leukemia after denileukin diftitox administration, suggesting that denileukin diftitox may affect the paracrine secretion of HTLV-1-associated clinical manifestations of ATL.

Original languageEnglish (US)
Pages (from-to)176-178
Number of pages3
JournalClinical Lymphoma
Volume4
Issue number3
StatePublished - Dec 2003
Externally publishedYes

Fingerprint

Adult T Cell Leukemia Lymphoma
Human T-lymphotropic virus 1
Vincristine
Doxorubicin
Cyclophosphamide
Dexamethasone
Primary Myelofibrosis
T-Lymphocytes
Hematopoiesis
Bone Marrow
Leukemic Infiltration
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Therapeutics
Leukocytosis
Thrombocytopenia
Disease Progression
Anemia
denileukin diftitox
Biopsy

Keywords

  • Hematopoiesis
  • Interleukin-2 receptor
  • Myelofibrosis

ASJC Scopus subject areas

  • Cancer Research

Cite this

Denileukin diftitox and hyper-CVAD in the treatment of human T-cell lymphotropic virus 1-associated adult T-cell leukemia/lymphoma. / DiVenuti, Gina; Nawgiri, Ranjana; Foss, Francine.

In: Clinical Lymphoma, Vol. 4, No. 3, 12.2003, p. 176-178.

Research output: Contribution to journalArticle

@article{bd7b6c1241c84d66ab920a5fd71ee941,
title = "Denileukin diftitox and hyper-CVAD in the treatment of human T-cell lymphotropic virus 1-associated adult T-cell leukemia/lymphoma",
abstract = "We report a case of human T-cell lymphotropic virus 1 (HTLV-1)-associated adult T cell leukemia/lymphoma (ATL) in clinical remission > 1 year after therapy with denileukin diftitox and hyper-CVAD (hyperfractionated cyclophosphamide/doxorubicin/vincristine/decadron). The patient presented with leukocytosis, anemia, and thrombocytopenia, and bone marrow biopsy demonstrated extensive myelofibrosis and infiltration with leukemic T cells. Initial therapy with 4 cycles of denileukin diftitox resulted in restoration of normal hematopoiesis and a reduction in bone marrow myelofibrosis. After disease progression, 4 cycles of hyper-CVAD were administered and a complete clinical remission was achieved. The patient remains free of disease with normal hematopoiesis and has continued maintenance therapy with denileukin diftitox for 1 year. This case demonstrates clinical improvement of myelofibrosis and acute T-cell leukemia after denileukin diftitox administration, suggesting that denileukin diftitox may affect the paracrine secretion of HTLV-1-associated clinical manifestations of ATL.",
keywords = "Hematopoiesis, Interleukin-2 receptor, Myelofibrosis",
author = "Gina DiVenuti and Ranjana Nawgiri and Francine Foss",
year = "2003",
month = "12",
language = "English (US)",
volume = "4",
pages = "176--178",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2650",
publisher = "Cancer Media Group",
number = "3",

}

TY - JOUR

T1 - Denileukin diftitox and hyper-CVAD in the treatment of human T-cell lymphotropic virus 1-associated adult T-cell leukemia/lymphoma

AU - DiVenuti, Gina

AU - Nawgiri, Ranjana

AU - Foss, Francine

PY - 2003/12

Y1 - 2003/12

N2 - We report a case of human T-cell lymphotropic virus 1 (HTLV-1)-associated adult T cell leukemia/lymphoma (ATL) in clinical remission > 1 year after therapy with denileukin diftitox and hyper-CVAD (hyperfractionated cyclophosphamide/doxorubicin/vincristine/decadron). The patient presented with leukocytosis, anemia, and thrombocytopenia, and bone marrow biopsy demonstrated extensive myelofibrosis and infiltration with leukemic T cells. Initial therapy with 4 cycles of denileukin diftitox resulted in restoration of normal hematopoiesis and a reduction in bone marrow myelofibrosis. After disease progression, 4 cycles of hyper-CVAD were administered and a complete clinical remission was achieved. The patient remains free of disease with normal hematopoiesis and has continued maintenance therapy with denileukin diftitox for 1 year. This case demonstrates clinical improvement of myelofibrosis and acute T-cell leukemia after denileukin diftitox administration, suggesting that denileukin diftitox may affect the paracrine secretion of HTLV-1-associated clinical manifestations of ATL.

AB - We report a case of human T-cell lymphotropic virus 1 (HTLV-1)-associated adult T cell leukemia/lymphoma (ATL) in clinical remission > 1 year after therapy with denileukin diftitox and hyper-CVAD (hyperfractionated cyclophosphamide/doxorubicin/vincristine/decadron). The patient presented with leukocytosis, anemia, and thrombocytopenia, and bone marrow biopsy demonstrated extensive myelofibrosis and infiltration with leukemic T cells. Initial therapy with 4 cycles of denileukin diftitox resulted in restoration of normal hematopoiesis and a reduction in bone marrow myelofibrosis. After disease progression, 4 cycles of hyper-CVAD were administered and a complete clinical remission was achieved. The patient remains free of disease with normal hematopoiesis and has continued maintenance therapy with denileukin diftitox for 1 year. This case demonstrates clinical improvement of myelofibrosis and acute T-cell leukemia after denileukin diftitox administration, suggesting that denileukin diftitox may affect the paracrine secretion of HTLV-1-associated clinical manifestations of ATL.

KW - Hematopoiesis

KW - Interleukin-2 receptor

KW - Myelofibrosis

UR - http://www.scopus.com/inward/record.url?scp=1642545477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642545477&partnerID=8YFLogxK

M3 - Article

C2 - 14715100

AN - SCOPUS:1642545477

VL - 4

SP - 176

EP - 178

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2650

IS - 3

ER -